Integrating digital images, data lakes, machine learning (ML), and artificial intelligence (AI), CelTivity uses two proprietary technologies integrated that delineate tissue microstructures and intracellular activity.
Inadequate real-time tissue assessment of biopsies from different cell types, like cancer cells, immune cells, granuloma, and others, forces proceduralists, such as bronchoscopists and radiologists, to choose between intraprocedural partial tissue adequacy assessment, rapid on-site evaluation (ROSE), or sending tissue samples for full pathology review. Neither truly answers the question, “Do we have enough cells to submit to pathology for the best chance of a conclusive diagnosis?” This can lead to prolonged delay for patient results, the need for a redo procedure, and potential delays for treatment options for the patient.
Consider lung biopsies, which are excised from patients and then sent to the laboratory for advanced cancer testing. These tests require that patients have an adequate amount of high-quality tissue to conduct advanced tests such as EGFR, kRas, or PD-1/PDL-1. To collect these biopsies, transthoracic needle biopsy (TTNA) is commonly used, whichrequires a needle to be inserted through the chest wall from outside the body. The risk of a collapsed lung (pneumothorax) can result in an average of 20% of procedures. Navigational bronchoscopy has emerged as a technology to collect lung biopsies with a lower risk of complications.
A better solution would be to assess tissue adequacy interprocedurally, to interrogate and image the biopsy in its entirety, to determine: Do we have the tissue? What exactly are we looking at (cancer cells, immune cells, granuloma)? And, do we have enough cells to submit to pathology to gain the best chance of a conclusive diagnosis? The results would allow clinicians intraprocedural identification and interpretation to properly assess tissue samples for adequacy.
CelTivity
Such a solution has recently been cleared by the FDA. Developed by Aquyre Biosciences, Inc. after a decade of research, CelTivity provides real-time cancer diagnostics of freshly excised cells and tissue in the operating room and private practice labs, effectively expanding advanced diagnosis capabilities.
"Integrating digital images, data lakes, machine learning and artificial intelligence,CelTivity utilizes two proprietary technologies integrated within one exam producing high-resolution images that delineate tissue microstructures and intracellular activity up to 1µm in 3D," says Bertrand Le Conte de Poly, CEO of Aquyre Biosciences. "These technologies are Full-Field Optical Coherence Tomography (FFOCT), and Dynamic Cell Imaging (DCI). Of significance, is that these diagnostic results are available within two minutes. The freshly excised sample can then be sent to pathology, along with the CelTivity data. Moreover, tissue depth exploration can be achieved at 150μm below the tissue surface with no cutting, staining, chemicals or sectioning required."